Skip to main content

Table 1 Participant characteristics stratified by HIV status

From: Cannabis use is not associated with increased balance disturbances in HIV-infected individuals

Variables HIV+ individuals (n = 2887) HIV− individuals (n = 761) Effect size (95% CI) p value
Demographics
 Age (years), mean (SD) 45.6 (11) 44.9 (14) 0.05 [− 0.02; 0.13]a 0.9
 Education, mean (SD) 12.9 (3) 13.6 (4) − 0.19 [− 0.27; − 0.11]a < .0001
 Male, n (%) 2333 (80.8%) 501 (65.8%) 2.18 [1.83; 2.61]b < .0001
 Ethnicity, n (%)
  Hispanic 503 (17.4) 147 (19.3%)   < .0001
  Non-Hispanic white 1328 (46) 430 (56.5%)  
  African American 958 (33.2) 136 (17.9%)  
  Asian 25 (0.9) 14 (1.9)  
  Other 73 (2.5) 34 (4.5)  
 BMI (kg/m2), mean (SD) 26.6 (10) 28.3 (6) − 0.17 [− 0.29; − 0.09]a < .0001
Cannabis use, n (%)
 Cannabis ever used, n (%) 1821 (74.9) 408 (72.6) 0.88 [0.72; 1.09]b 0.2
 Lifetime years cannabis use, mean (SD) 6.9 (8.4) 7.2 (9.5) − 0.03 [− 0.14; 0.07]a 0.5
 Lifetime quantity cannabis (grams), mean (SD) 4724 (12775) 4515 (11627) 0.01 [− 0.09; 0.12]a 0.6
Medication currently used, n (%)
 Opioids, n (%) 480 (16.6) 53 (6.9) 2.66 [1.98; 3.58]b <.0001
 Sedatives, n (%) 365 (12.6) 39 (5.1) 2.75 [1.95; 3.87]b <.0001
 Antihypertensives, n (%) 223 (7.7) 65 (8.5) 0.9 [0.67; 1.21]b 0.5
Neurological disease, n (%)
 cDSPN signs, n (%) 1574 (54.5) 190 (24.9) 3.60 [3.00; 4.31]b <.0001
 Gait ataxia, n (%) 130 (4.5) 20 (2.6) 1.74 [1.08; 2.81]b 0.02
  1. Effect size presented as aCohen’s d or bodds ratios
  2. CI confidence interval, BMI body mass index, cDSPN chronic distal sensory polyneuropathy